OncLive TV

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the use of metastasis-directed therapy in prostate cancer.

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Kathleen Moore, MD, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.

Michael A. Choti, MD, discusses the future of treatment for patients with stage IV pancreatic cancer.

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

John M. Pagel, MD, PhD, discusses the phase III ELEVATE-TN trial in chronic lymphocytic leukemia.

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Mira Hellmann, MD, discusses the utility of minimally invasive surgery in cervical cancer.

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.